S. Siesling

Early detection of symptoms using electronic patient-reported outcomes and a Fitbit to optimise care in metastatic breast cancer: study protocol of the SYMPHA trial

Therapeutic strategies for patients with metastatic breast cancer (mBC) are aimed at prolonging survival while preserving health-related quality of life (HRQoL). Current systemic therapies, however, are frequently associated with severe toxicities that impair HRQoL. Early detection of symptoms related to treatmen...

A Decade of Change: Systemic Treatment Patterns in Clinically Small HER2-Positive Node-Negative Breast Cancer in the Netherlands: A Population-Based Study.

Exploring sex differences in global cancer incidence and mortality and the role of national development level

Background We analysed sex differences in global cancer incidence and mortality using a national development index to better understand how broader socioeconomic factors may contribute to or mitigate sex differences in cancer outcomes. Materials and methods Cancer incidence and mortality data (2012-2017) were obtained...

Belgian validation of the INFLUENCE 3.0 model predicting 5-year locoregional and contralateral breast cancer recurrence.

BACKGROUND Breast cancer (BC) surveillance primarily aims to detect locoregional recurrence (LRR) and contralateral breast cancer (CBC), but current strategies are largely one-size-fits-all and not tailored to individual risks. The Dutch INFLUENCE 3.0 prediction model provides personalised 5-year LRR and CBC risks to s...